Abstract: A pharmaceutical for prevention and treatment of demyelination-associated neural function impairing diseases contains erythropoietin as an active ingredient, and protectively act on the survival of oligodendrocytes, which form a myelin sheath, in cerebrovascular dementia typified by multiple sclerosis and Binswanger disease, diseases involving demyelination. The pharmaceutical and method also promote maturation of undifferentiated oligodendrocytes present in the brain, activating remyelination. Through these mechanisms, the pharmaceutical and method can prevent and treat demyelination-associated neural function impairing diseases.

Abstract: When a pharmaceutical composition for preventing and/or treating peripheral neuropathy caused by chromosomal microtubule inhibition, which comprises erythropoietin as an active ingredient, is administered to patients receiving a microtubule inhibitor as an anticancer agent, such treatment alleviates peripheral neuropathy in the patients and enables increased dosage, prolonged period and increased frequency for administration of the above anticancer agent, which were never before achieved. Thus, the pharmaceutical composition not only contributes to improvement of QOL in the patients, but also enables prolongation of life in the patients.

Abstract: A pharmaceutical for prevention and treatment of demyelination-associated neural function impairing diseases, the pharmaceutical containing erythropoietin as an active ingredient, and a method for prevention and treatment of the diseases are provided. The preventive and therapeutic pharmaceutical and method of the present invention protectively act on the survival of oligodendrocytes, which form a myelin sheath, in cerebrovascular dementia typified by multiple sclerosis and Binswanger disease, diseases involving demyelination. The pharmaceutical and method also promote maturation of undifferentiated oligodendrocytes present in the brain, activating remyelination. Through these mechanisms, the pharmaceutical and method can prevent and treat demyelination-associated neural function impairing diseases.

Abstract: The activity of an expression product of a gene introduced into a living body can be regulated by the coexistence of a protein (interfering substance) that interferes with the activity of the expression product. Receptors of the expression product and such may be used as the interfering substance. The activity of an overexpressed product of a gene introduced in gene therapy can be regulated. The administration of an interfering substance can be achieved by in vivo expression of the gene encoding the substance.

Abstract: Disclosed is a therapeutic agent for the treatment of peripheral circulatory disorders that contains as the effective ingredient a dibenzoxazepin derivative of the following formula or a pharmaceutically acceptable salt thereof: ##STR1## where R.sub.1 is a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; R.sub.2 is a hydrogen atom or a lower alkyl group; and A signifies the group ##STR2## (where R.sub.3 is a hydrogen atom, a lower alkyl group, an optionally substituted phenyl group or a styryl group). Also, disclosed is a method for treatment of peripheral circulatory disorders by administering the compound of the formula (I) or a pharmaceutically acceptable salt thereof to a patient suffering from such disorders.